Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cspc Ouyi Pharmaceutical Co. Ltd. maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio features 1 pending office action. This action is located within 1 distinct art unit, indicating a specific technical focus for the company's current intellectual property activities. For the applicant, this concentration in 1 art unit suggests that the examiner's review will be informed by a very specific set of prior art and technical standards common to that division.
The prosecution is managed by 1 distinct examiner, MAHLUM, JONATHAN DAVIS. As the busiest examiner, MAHLUM, JONATHAN DAVIS is assigned 1 busiest examiner pending action. Given that the total count of pending office actions is 1, this single examiner controls the entire active docket for the company. This 1 to 1 ratio between total pending actions and those assigned to the busiest examiner shows that all current legal hurdles for the company are consolidated under a single individual's review. This means the applicant's current strategy must be tailored to the specific expectations of MAHLUM, JONATHAN DAVIS, as there are no other examiners or art units currently influencing the portfolio's progression.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAHLUM, JONATHAN DAVIS | 1 | 51.4% | +25.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280868 | USE OF A COMPOUND CONTAINING A TRICYCLIC HETEROARYL GROUP | MAHLUM, JONATHAN DAVIS | 19d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280868 | USE OF A COMPOUND CONTAINING A TRICYCLIC HETEROARYL GROUP | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 19d | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial